Cambrex sells drug product business; Landmark to work with Galapagos; Genezen locks $18.5M equity boost
Welcome to Endpoints News’ manufacturing news briefs, where we bring you essential updates on new builds, collaborations, recalls and more.
CDMO Cambrex sold its drug product business unit to API supplier Noramco, according to a Nov. 2 press release. As a part of the purchase, Noramco will revert back to its Halo Pharmaceutical brand name. The business unit, with facilities in Québec, Canada, and Whippany, NJ, offers clinical and commercial manufacturing and packaging services, among others.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.